BeOne Medicines’ fair value estimate has nudged higher to about $402 per share, even as the assumed revenue growth rate eases slightly to roughly 17.20%. This reflects a more balanced long term outlook. Analysts see this as the market recalibrating around stronger clinical execution and a deeper, more visible oncology pipeline, while a marginally higher discount rate keeps expectations in check. R...
BeOne Medicines’ fair value estimate has nudged higher to about $402 per share, even as the assumed revenue growth rate eases slightly to roughly 17.20%. This reflects a more balanced long term outlook. Analysts see this as the market recalibrating around stronger clinical execution and a deeper, more visible oncology pipeline, while a marginally higher discount rate keeps expectations in check. Read on to see how you can track these shifting targets and stay ahead of the evolving BeOne...